Cancer Vaccine Specialist Targovax Appoints Gunnar Gårdemyr As New CEO

NORWAY -- The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO of the company from January 12th, 2015.

Mr Gårdemyr has more than 30 years of international experience in the pharmaceutical and biotech industry, including management, business development, mergers & acquisitions, global marketing and commercial strategy. He currently holds the position of Corporate Advisor for Acino Pharma in Basel, Switzerland. Prior to this he was Senior Vice President, Corporate Development/M&A, Global Business Development, Nycomed and Senior Vice President, Global Marketing, Takeda in Zurich, Switzerland, where he was in charge of the commercial assessment of external business development licensing opportunities.

Mr Gårdemyr started his career in Astra, followed by Ferring, Tigran Technologies and Retinalyze.

He has a Bachelor of Science in Business Administration and Economics from the University of Lund, Sweden.

Jónas Einarsson, Chairman of Targovax, comments: "We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar's track record and knowledge reflects Targovax` potential. His leadership will accelerate the company's further development.

"We are also very grateful to Hanne Mette D. Kristensen for her contribution by leading Targovax from establishment to a phase II company." 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.